Corning® Supersomes™ Human UGT1A3, 0.5 mL Recombinant enzyme prepared from insect cells infected with baculovirus containing human UGT1A3 cDNAs
UDP-glucuronosyltransferases (UGT) represent the major phase II drug metabolism pathway in human. UGT enzymes catalyze the transfer of glucuronic acid (derived from UDPGA co-factor) to xenobiotics and endogenous substrates having nucleophilic acceptor groups, making them more polar and readily excreted in urine or bile. To date, at least 18 human UGT enzymes have been cloned and sequenced. Like the P450 enzymes, UGTs possess broad and overlapping substrate specificities. Clinically relevant drug interactions have been identified for UGT isoforms, leading regulatory agencies (FDA) to require drug interaction testing for compounds showing significant UGT metabolism.
UGT1A3 is expressed in the liver and intestine. It is involved in the metabolism of several drug substrates. Selective substrates for UGT1A3 include R-lorazepam and 25-hydroxy vitamin D3. The specificity of UGT1A3 shows some overlap with UGT1A1; e.g. UGT1A3 has been shown to glucuronidate ß-estradiol.